Ardelyx decided to shutter development of RDX7675 – an experimental medicine for hyperkalemia – including the onset-of-action trial and Phase III studies.

As part of its strategic review and second-quarter 2017 financial reporting, Ardelyx announced the company planned to cut 28 percent of its workforce.

The U.S. Food and Drug Administration gave AstraZeneca’s New Drug Application for ZS-9 (sodium zirconium cyclosiliate) a Complete Response Letter (CRL) — again. The drug was being developed for hyperkalemia by ZS Pharma, a wholly owned subsidiary of AstraZeneca.

Fremont, Calif.-based Ardelyx announced that its Phase III clinical trial of tenapanor for hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis met its primary endpoint.

Redwood City, California-based Relypsa disclosed prescription sales information for Veltassa that led to a stock decline of 7.8 percent.

LONDON – Looking to strengthen its cardiovascular and metabolic offerings, London-based AstraZeneca (AZN) is snapping up Bay Area-based ZS Pharma (ZSPH) in a deal worth $2.7 billion in hopes of leveraging that company’s ion-trap technology treatments for hyperkalemia into a blockbuster drug. The deal, which will see AstraZeneca spend $90 per share for ZS Pharma, […]

The U.S. Food and Drug Administration approved Relypsa Inc’s drug to treat potentially fatal levels of potassium in patients with chronic kidney disease or heart problems. The drug, Veltassa, is designed to treat hyperkalemia, a chronic condition characterized by excessive potassium levels in the blood that could lead to dangerous changes in heart rhythm. Relypsa’s […]

Switzerland-based Actelion Ltd. (ALIOF.PK) last week confirmed that it was in talks to acquire ZA Pharma Inc. As a result, the stock dropped about 3.2 percent overnight. ZS Pharma (ZSPH), headquartered in Mateo, Calif., found its stock price jumping 28 percent.   Actelion focuses on pulmonary arterial hypertension (PAH) and markets Veletri, Tracleer and Opsumit. […]

Redwood City, Calif.-based Relypsa Inc. (RLYP) announced yesterday that it had signed a two-year detailing deal with Sanofi for the commercialization of a kidney disease drug. It also announced today an exclusive partnership with St. Gallen, Switzerland-based Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP) for the same drug in Europe and additional territories.   […]